title: Medical management of hepatorenal syndrome.
abstract: Hepatorenal syndrome (HRS) is defined as the occurrence of renal dysfunction in a patient with end-stage liver cirrhosis in the absence of another identifiable cause of renal failure. The prognosis of HRS remains poor, with a median survival without liver transplantation of <6 months. However, understanding the pathogenesis of HRS has led to the introduction of treatments designed to increase renal perfusion and mean arterial blood pressure using vasopressors and albumin, which has led to improvement in renal function in ∼50% of patients.
authors.affiliation: Department of Medicine, University College London Medical School, London, UK. Andrewdavenport@nhs.net
authors.forename: Andrew
authors.initials: A
authors.lastname: Davenport
authors.forename: Jawad
authors.initials: J
authors.lastname: Ahmad
authors.forename: Ali
authors.initials: A
authors.lastname: Al-Khafaji
authors.forename: John A
authors.initials: JA
authors.lastname: Kellum
authors.forename: Yuri S
authors.initials: YS
authors.lastname: Genyk
authors.forename: Mitra K
authors.initials: MK
authors.lastname: Nadim
mesh_terms: D019468:Disease Management; D006530:Hepatorenal Syndrome / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications* / Q000628:therapy; D016031:Liver Transplantation / Q000009:adverse effects*; D011379:Prognosis; D051437:Renal Insufficiency / Q000209:etiology* / Q000628:therapy